Carbon Biosciences appoints Dr. Carol Satler to its Board as Independent Director

– USA, MA –  Carbon Biosciences, a preclinical stage biotechnology company developing genetic medicines for the treatment of pulmonary and cardiac diseases, announced the appointment of Dr. Carol Satler (MD, PhD, FACC, FAHA, FAAP) to its Board as an Independent Director.

About Dr. Carol Ann Satler

Dr. Satler is a physician executive with demonstrated success in clinical development and medical affairs in high-growth, innovative companies. Her work has included strategic clinical development planning, launching, and commercialization of products for chronic diseases such as idiopathic pulmonary fibrosis and heart failure. Dr. Satler currently serves as lead medical director for the clinical development idiopathic pulmonary fibrosis program at PureTech Health and as an Independent Board Member for ViCardia Therapeutics. She was previously President, Chief Medical Officer, and Board Member of Respira Therapeutics.

Dr. Satler is a graduate of the MD-PhD program at Case Western Reserve University, Cleveland, Ohio. She trained and practiced in both pediatric medicine and cardiology at Boston Children’s Hospital and served on the faculty of Harvard Medical School. She has been elected a Fellow of the American College of Cardiology, American Heart Association, and American Academy of Pediatrics.

About Carbon Biosciences

Carbon Biosciences is a team of passionate drug developers extending the reach of genetic medicines for the treatment of devastating diseases. We combine the genetic diversity and potency of viruses that have evolved over millions of years with the recent clinical and manufacturing advances in the gene therapy field. Our proprietary platform, PAVE, has the potential advantages of exquisite tissue specificity, larger payloads, and durable treatment strategies across multiple modalities. Our goal: realize the power of natural viral evolution and deliver on the promise of genetic medicines.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.